Cat. No.: HY-A0021

Palonosetron hydrochloride

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Palonosetron hydrochloride is a 5-HT3 antagonist primarily used to prevent acute, delayed, and overall chemotherapy-induced nausea and vomiting. In addition, Palonosetron hydrochloride exhibits moderate anti-flavivirus activity and potent anti-Zika virus activity in mammalian cells. Palonosetron hydrochloride also possesses antidepressant activity.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 135729-62-3
Formula: C₁₉H₂₅ClN₂O
Molecular Weight:332.87

Storage:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Palonosetron hydrochloride Chemical Structure

CAS No.: 135729-62-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

5-HT₃ Receptor

All 5-HT Receptor Isoforms :

In Vitro

Palonosetron (10 nM, 2 hours) hydrochloride inhibits the enhancement effect of 5-HT on substance P (SP)-induced calcium release in NG108-15 cells, increasing the EC₅₀ of SP from 0.62 µM to 3.7 µM^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Palonosetron (0.05 mg/kg, i.p., single dose) hydrochloride significantly reduces immobility in Swiss albino mice, demonstrating potential antidepressant activity^[5].
alonosetron (30-300 µg/kg, i.v., single dose) hydrochloride dose-dependently inhibits SP-mediated neuronal responses in the Cisplatin (HY-17394)-induced rat emesis model, indicating its impact on neurotransmission^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Swiss albino mice (25-40 g)^[5]
Dosage:

0.025 and 0.05 mg/kg
Administration:

Intraperitoneal injection (i.p.), single dose, efficacy tested after 1 hour and 24 hours
Result:

Reduced immobility time in a dose-dependent manner. The 0.05 mg/kg dose significantly reduced immobility time after 1 hour and 24 hours.

Animal Model:

Cisplatin-induced emesis model in adult male Sprague-Dawley rats (270-350 g)^[6]
Dosage:

30 µg/kg, 100 µg/kg, 300 µg/kg
Administration:

Intravenous injection (i.v.), single dose
Result:

Dose-dependently inhibited the Cisplatin (HY-17394)-induced enhancement of neuronal response to substance P (SP) in the nodose ganglia.

Chemical Information

CAS No. 135729-62-3
Appearance Solid
Molecular Weight 332.87
Formula C₁₉H₂₅ClN₂O
Color White to off-white
SMILES

O=C1N(C[C@@]([H])(CCC2)C3=C2C=CC=C13)[C@@H]4CN5CCC4CC5.[H]Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (2)

All

Sort by:

Journal Impact Factor

PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Virus Res

Ondansetron exhibits potent antiviral activity against enterovirus 71 infection in vitro and in vivo. [Abstract]

2026 Jun 25:370:199771. PMID: 42349797

Solvent & Solubility

In Vitro:

H₂O : 100 mg/mL (300.42 mM; Need ultrasonic)

DMSO : 3.33 mg/mL (10.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0042 mL

15.0209 mL

30.0418 mL

5 mM

0.6008 mL

3.0042 mL

6.0084 mL

10 mM

0.3004 mL

1.5021 mL

3.0042 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution

This protocol yields a clear solution of ≥ 0.33 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (3.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution

This protocol yields a clear solution of ≥ 0.33 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (3.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.33 mg/mL (0.99 mM); Clear solution

This protocol yields a clear solution of ≥ 0.33 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (3.3 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (300.42 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Barrows, et al. "A screen of FDA-approved drugs for inhibitors of Zika virus infection." Cell host & microbe 20.2 (2016): 259-270. [Content Brief]

[2]. Rojas, et al. "Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor." Anesthesia & Analgesia 107.2 (2008): 469-478. [Content Brief]

[3]. Wallenborn, et al. "Palonosetron hydrochloride in the prevention and treatment of postoperative nausea and vomiting." Clinical Medicine Insights: Therapeutics 2 (2010): CMT-S4016.

[4]. Sepúlveda-Vildósola, et al. "Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children." Archives of medical research 39.6 (2008): 601-606. [Content Brief]

[5]. Sharma J, et al. Evaluation of antidepressant effect of palonosetron in Swiss albino mice[J]. National Journal of Pharmacology and Therapeutics, 2023, 1(2): 98-100.

[6]. Rojas C, et al. The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther. 2010 Nov;335(2):362-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	3.0042 mL	15.0209 mL	30.0418 mL	75.1044 mL
DMSO / H₂O	5 mM	0.6008 mL	3.0042 mL	6.0084 mL	15.0209 mL
H₂O	15 mM	0.2003 mL	1.0014 mL	2.0028 mL	5.0070 mL
	20 mM	0.1502 mL	0.7510 mL	1.5021 mL	3.7552 mL
	25 mM	0.1202 mL	0.6008 mL	1.2017 mL	3.0042 mL
	30 mM	0.1001 mL	0.5007 mL	1.0014 mL	2.5035 mL
	40 mM	0.0751 mL	0.3755 mL	0.7510 mL	1.8776 mL
	50 mM	0.0601 mL	0.3004 mL	0.6008 mL	1.5021 mL
	60 mM	0.0501 mL	0.2503 mL	0.5007 mL	1.2517 mL
	80 mM	0.0376 mL	0.1878 mL	0.3755 mL	0.9388 mL
	100 mM	0.0300 mL	0.1502 mL	0.3004 mL	0.7510 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Palonosetron hydrochloride

2 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Palonosetron hydrochloride

Bioactive Compound Library Max

Bioactive Compound Library

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Pediatric Drug Library

Antidepressant Compound Library

Chemotherapy Drug Library

EMA-Approved Drug Library

5-HT Receptor Compound Library

FDA-Approved Anticancer Drug Library

Coagulation and Anti-coagulation Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Multi-Target Compound Library

MCE Bioactive Compound Library

Natural Product-like Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Palonosetron hydrochloride

All 5-HT Receptor Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Palonosetron hydrochloride Related Classifications

HY-A0021 Related Classifications